CA2223402C - Procedes d'inhibition de la phagocytose - Google Patents

Procedes d'inhibition de la phagocytose Download PDF

Info

Publication number
CA2223402C
CA2223402C CA2223402A CA2223402A CA2223402C CA 2223402 C CA2223402 C CA 2223402C CA 2223402 A CA2223402 A CA 2223402A CA 2223402 A CA2223402 A CA 2223402A CA 2223402 C CA2223402 C CA 2223402C
Authority
CA
Canada
Prior art keywords
nucleic acid
mrna
syk
complementary
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2223402A
Other languages
English (en)
Other versions
CA2223402A1 (fr
Inventor
Alan D. Schreiber
Jong-Gu Park
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Original Assignee
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania Penn filed Critical University of Pennsylvania Penn
Publication of CA2223402A1 publication Critical patent/CA2223402A1/fr
Application granted granted Critical
Publication of CA2223402C publication Critical patent/CA2223402C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention se rapporte, en général, à des procédés de traitement de maladies dues à des interactions entre des complexes immuns et des récepteurs Fc. La présente invention se rapporte notamment à des procédés permettant de moduler l'élimination de la circulation de cellules recouvertes d'anticorps, qui consistent à inhiber la phagocytose, et à des procédés de modulation de l'interaction des complexes immuns avec les récepteurs Fc des tissus. L'invention se rapporte en outre à des procédés de modulation de l'activation des processus immunologiques induits par l'activation des récepteurs Fc due à l'interaction anticorps-antigènes/récepteurs.
CA2223402A 1995-06-07 1996-06-07 Procedes d'inhibition de la phagocytose Expired - Fee Related CA2223402C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48353095A 1995-06-07 1995-06-07
US08/483,530 1995-06-07
PCT/US1996/010494 WO1996040199A1 (fr) 1995-06-07 1996-06-07 Procedes d'inhibition de la phagocytose

Publications (2)

Publication Number Publication Date
CA2223402A1 CA2223402A1 (fr) 1996-12-19
CA2223402C true CA2223402C (fr) 2012-07-31

Family

ID=23920431

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2223402A Expired - Fee Related CA2223402C (fr) 1995-06-07 1996-06-07 Procedes d'inhibition de la phagocytose

Country Status (6)

Country Link
EP (1) EP0831875A4 (fr)
JP (1) JPH11507824A (fr)
AU (1) AU723595B2 (fr)
CA (1) CA2223402C (fr)
IL (1) IL122338A0 (fr)
WO (1) WO1996040199A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8039026B1 (en) 1997-07-28 2011-10-18 Johnson & Johnson Consumer Companies, Inc Methods for treating skin pigmentation
US8106094B2 (en) 1998-07-06 2012-01-31 Johnson & Johnson Consumer Companies, Inc. Compositions and methods for treating skin conditions
US8093293B2 (en) 1998-07-06 2012-01-10 Johnson & Johnson Consumer Companies, Inc. Methods for treating skin conditions
GB9822763D0 (en) * 1998-10-20 1998-12-16 Univ Sheffield Immunoglobin variant
EP1006183A1 (fr) 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Récepteurs Fc recombinantes et solubles
US7985404B1 (en) 1999-07-27 2011-07-26 Johnson & Johnson Consumer Companies, Inc. Reducing hair growth, hair follicle and hair shaft size and hair pigmentation
US8431550B2 (en) 2000-10-27 2013-04-30 Johnson & Johnson Consumer Companies, Inc. Topical anti-cancer compositions and methods of use thereof
US7192615B2 (en) 2001-02-28 2007-03-20 J&J Consumer Companies, Inc. Compositions containing legume products
WO2002089832A2 (fr) * 2001-05-09 2002-11-14 Alk-Abelló A/S Compositions pharmaceutiques destines a prevenir ou traiter les maladies associees aux cellules th1 et th2 par modulation du rapport th1/th2
US20050267059A1 (en) 2003-11-14 2005-12-01 Diana Beardsley Syk-targeted nucleic acid interference
TW200808360A (en) * 2006-04-13 2008-02-16 Alcon Mfg Ltd RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions
GB201509413D0 (en) * 2015-06-01 2015-07-15 Ucl Business Plc Fusion protein

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111105A (en) * 1993-09-30 2009-05-04 Univ Pennsylvania Use of a molecule capable of inhibiting the expression of syk kinase to prepare a pharmaceutical composition for inhibiting phagocytosis
US5641863A (en) * 1993-09-30 1997-06-24 University Of Pennsylvania Chimeric IgG Fc receptors
AU682226B2 (en) * 1993-11-23 1997-09-25 Ciba Corning Diagnostics Corp. Use of antisense oligomers in a process for controlling contamination in nucleic acid amplification reactions

Also Published As

Publication number Publication date
AU723595B2 (en) 2000-08-31
CA2223402A1 (fr) 1996-12-19
EP0831875A4 (fr) 2002-07-31
IL122338A0 (en) 1998-04-05
AU6386996A (en) 1996-12-30
WO1996040199A1 (fr) 1996-12-19
EP0831875A1 (fr) 1998-04-01
JPH11507824A (ja) 1999-07-13

Similar Documents

Publication Publication Date Title
US5858981A (en) Method of inhibiting phagocytosis
Tiwari-Woodruff et al. OSP/claudin-11 forms a complex with a novel member of the tetraspanin super family and β1 integrin and regulates proliferation and migration of oligodendrocytes
US8114603B2 (en) TREM-1 splice variant for use in modifying immune responses
Li et al. A cdc15‐like adaptor protein (CD2BP1) interacts with the CD2 cytoplasmic domain and regulates CD2‐triggered adhesion
JP2006217922A (ja) 食作用を阻害する方法
US20150197565A1 (en) Novel ligand
CA2223402C (fr) Procedes d'inhibition de la phagocytose
Abdelilah et al. Molecular characterization of the low-affinity IgE receptor Fc epsilonRII/CD23 expressed by human eosinophils.
Versteeg et al. High expression of the c-myc oncogene renders melanoma cells prone to lysis by natural killer cells.
WO1996040199A9 (fr) Procedes d'inhibition de la phagocytose
Rother et al. Expression of recombinant transmembrane CD59 in paroxysmal nocturnal hemoglobinuria B cells confers resistance to human complement
AU724246B2 (en) Cytoplasmic modulators of integrin regulation/signaling
JP2003189874A (ja) ガレクチン−９活性制御剤
MXPA01009491A (es) Moleculas de acido desoxirribonucleico (adn) que codifican para proteinas clax humanas y sus proteinas de fusion solubles.
AU748168B2 (en) Viral encoded semaphorin protein receptor DNA and polypeptides
JP3621883B2 (ja) ウイルスがコードするセマフォリンタンパク質受容体ｄｎａおよびポリペプチド
Douhan III Noncoordinate regulation of the human and murine major histocompatibility complex class II genes
WO2004048574A1 (fr) Proteines d'immunorecepteurs
Bannish Transcriptional regulation of MHC class II expression in class II negative B cell lines
YIRU Site-directed mutagenesis of CD38 in cho tet-off cells
AU2002246642A1 (en) TREM-1 Splice variant for use in modifying immune responses

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20140609